Literature DB >> 29221367

Target blood pressure in high risk cardiovascular patients.

Dominic Millenaar1, Sebastian Ewen1, Felix Mahfoud1, Michael Böhm1.   

Abstract

Entities:  

Year:  2017        PMID： 29221367      PMCID： PMC5708449          DOI： 10.21037/jtd.2017.08.88

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Will SPRINT change my practice? SPRINT: a randomised trial of intensive versus standard blood-pressure control.

Authors:  Sebastian Ewen; Melvin D Lobo; Atul Pathak; Roland E Schmieder; Costas Tsioufis; William Wijns; Felix Mahfoud
Journal:  EuroIntervention       Date:  2016-08-20       Impact factor: 6.534

Review 2.  Pulse pressure as an independent predictor of stroke: a systematic review and a meta-analysis.

Authors:  Feng-Di Liu; Xiao-Lei Shen; Rong Zhao; Xiao-Xiao Tao; Shuo Wang; Jia-Jun Zhou; Bo Zheng; Qi-Ting Zhang; Qian Yao; Ying Zhao; Xin Zhang; Xue-Mei Wang; Hui-Qin Liu; Liang Shu; Jian-Ren Liu
Journal:  Clin Res Cardiol       Date:  2016-02-22       Impact factor: 5.460

3.  Coronary flow reserve in patients with resistant hypertension.

Authors:  Sebastian Völz; Sara Svedlund; Bert Andersson; Gan Li-Ming; Bengt Rundqvist
Journal:  Clin Res Cardiol       Date:  2016-10-17       Impact factor: 5.460

4.  Target blood pressure and cardiovascular risk.

Authors:  Céline Dreyfuss-Tubiana; Philippe Sosner; Jacques Blacher
Journal:  J Thorac Dis       Date:  2017-07       Impact factor: 2.895

5.  Beneficial effects of renal sympathetic denervation on cardiovascular inflammation and remodeling in essential hypertension.

Authors:  Oliver Dörr; Christoph Liebetrau; Helge Möllmann; Felix Mahfoud; Sebastian Ewen; Luise Gaede; Christian Troidl; Jedrzej Hoffmann; Nikolai Busch; Gerald Laux; Jens Wiebe; Timm Bauer; Christian Hamm; Holger Nef
Journal:  Clin Res Cardiol       Date:  2014-10-18       Impact factor: 5.460

6.  Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.

Authors:  Michael Böhm; Helmut Schumacher; Koon K Teo; Eva M Lonn; Felix Mahfoud; Johannes F E Mann; Giuseppe Mancia; Josep Redon; Roland E Schmieder; Karen Sliwa; Michael A Weber; Bryan Williams; Salim Yusuf
Journal:  Lancet       Date:  2017-04-05       Impact factor: 79.321

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

8.  Use of automated office blood pressure measurement to reduce the white coat response.

Authors:  Martin G Myers; Miguel Valdivieso; Alexander Kiss
Journal:  J Hypertens       Date:  2009-02       Impact factor: 4.844

9.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321

10.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control.

Authors:  Jackson T Wright; Jeff D Williamson; Paul K Whelton; Joni K Snyder; Kaycee M Sink; Michael V Rocco; David M Reboussin; Mahboob Rahman; Suzanne Oparil; Cora E Lewis; Paul L Kimmel; Karen C Johnson; David C Goff; Lawrence J Fine; Jeffrey A Cutler; William C Cushman; Alfred K Cheung; Walter T Ambrosius
Journal:  N Engl J Med       Date:  2015-11-09       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.